Opportunities of topical drug products in a changing dermatological landscape.

Despite the prevalence and the impact on quality of life of dermatological indications, drug products to treat such conditions have rarely been blockbusters. The prevailing perception of a limited commercial potential of dermatological drug products has restricted innovation and encouraged a more conservative development approach. For example, the focus was on repurposing/reformulation of existing active pharmaceutical ingredients (APIs) specifically for the topical delivery route.

Rational Design of Topical Semi-Solid Dosage Forms-How Far Are We?

Specific aspects of semi-solid dosage forms for topical application include the nature of the barrier to be overcome, aspects of susceptibility to physical and chemical instability, and a greater influence of sensory perception. Advances in understanding the driving forces of skin penetration as well as the design principles and inner structure of formulations, provide a good basis for the more rational design of such dosage forms, which still often follow more traditional design approaches. This review analyses the opportunities and constraints of rational formulation design approaches in the industrial development of new topical drugs.

New Complexes of Antimony(III) with Tridentate ,,-Ligands (E = O, S, Se, Te, NH, NMe) Derived from -Methyldiethanolamine.

We synthesized a series of new antimony(III) compounds by reaction of Sb(OEt) with organic ligands of the type E(CH-CH-OH), with E = NH, NMe, O, S, Se, and Te. The synthesized compounds have the general composition [E(CH-CH-O)]Sb(OEt). For comparison, the compound (O-CH-CH-S)Sb(OEt) was prepared.

9-(Pyrrolidinium-1-yl)-9-boranuidabi-cyclo-[3.3.1]nona-ne.

The title compound, CHBN, is an adduct formed from 9-borabi-cyclo-[3.3.1]nonane (9-BBN) and pyrrolidine.